{"id":1022495,"date":"2026-11-19T07:06:00","date_gmt":"2026-11-19T12:06:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/"},"modified":"2026-11-19T07:06:00","modified_gmt":"2026-11-19T12:06:00","slug":"marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/","title":{"rendered":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma<\/em>\n      <\/p>\n<p align=\"justify\">HOUSTON, Nov.  19, 2026  (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funding will support the advancement of the Company\u2019s lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in the planned Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma (LBCL) following treatment with CD19-directed chimeric antigen receptor (CAR)-T cells.<\/p>\n<p align=\"justify\">The CPRIT Product Development Research program is a highly competitive funding initiative established by the State of Texas to advance innovative cancer therapies toward commercialization. Applications undergo a rigorous multistage evaluation involving independent scientific and industry experts, including assessment of scientific merit, clinical development strategy, regulatory considerations, intellectual property, manufacturing feasibility, and commercial potential. For this funding cycle, CPRIT received 207 applications and awarded a total of $74.3 million to 12 projects.<\/p>\n<p align=\"justify\">\u201cSecuring this $16.2 million award from CPRIT is an important milestone for Marker and further reinforces our confidence in the potential of MT-601 in CAR-relapsed lymphoma,\u201d said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. \u201cFollowing a highly competitive selection and review process, this award provides meaningful external recognition of our differentiated MAR-T cell approach and substantial non-dilutive funding to support our Phase 2 APOLLO study to translate our early clinical findings into a much-needed new treatment option for patients with limited therapeutic alternatives. We look forward to providing updated clinical results later this year and advancing MT-601 through its next stage of clinical development.\u201d<\/p>\n<p align=\"justify\">The CPRIT award builds on encouraging clinical results from the Phase 1 APOLLO study (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=azlJs48yBhVvHgBB9LSQ0gfApqIo9CyFUNyA_9RkvAanyYO4HjERw5cCONzyPOE81jJy8Y8jBxkeG4g_0ItHzHQiyBuQAUvBTIpzDS8cP1I=\" rel=\"nofollow\" target=\"_blank\">clinicaltrials.gov<\/a> identifier: NCT05798897) evaluating MT-601 in patients with heavily pretreated lymphoma, including patients who had previously received CAR-T cells and bispecific antibodies. In August 2025, Marker reported a 66% objective response rate and a 50% complete response rate among 12 evaluable patients with non-Hodgkin lymphoma. Durable responses were observed, including responses lasting up to 24 months at the time of the data cutoff (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wbK4FsQmepP-ulh1uyoRP9nMT-XwLSn8hFZLgi-MgMQDmSe-0cm4fe7rCM5nSYC3XZOyXrlfkLBpE16-YZ0ubChkY5-m7asridaUmmMInaPbSr9d4t3U8S8QqRW7exZd8W3q0CN6CeV5Qx0Z7L-kskXxgyRkFlvZ-ZyVw4nQO5XKvuJm3q_HCYEu_R6jarelLx5iRAYl1iuB4dj4AoNutLA7EWF059bmHCduaOCfB0iD7G0_Iu7yin1VxaAsAwCI\" rel=\"nofollow\" target=\"_blank\">Press Release, August 26, 2025<\/a>). MT-601 also demonstrated a favorable safety profile across evaluated dose levels, with no dose-limiting toxicities or immune-effector cell-associated neurotoxicity syndrome (ICANS).<\/p>\n<p align=\"justify\">\u201cDespite significant advances in the treatment of large B-cell lymphoma, patients who relapse following CAR-T therapy continue to face limited treatment options and poor clinical outcomes,\u201d commented Geoffrey Shouse, D.O., Ph.D., Principal Investigator at City of Hope National Medical Center in Duarte, California. \u201cThrough our experience with MT-601 in the Phase 1 APOLLO study, we have observed encouraging clinical activity and a favorable safety profile in heavily pretreated patients, including those who have progressed following multiple prior lines of therapy. We believe MT-601 represents a promising therapeutic approach and has the potential to meaningfully change the treatment landscape for patients with LBCL who relapse after CAR-T therapy.\u201d<\/p>\n<p align=\"justify\">The CPRIT award further strengthens Marker\u2019s track record of securing competitive federal and state funding to support the Company\u2019s innovative MAR-T cell platform. The award builds on previously secured non-dilutive funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the Phase 1 clinical development of MT-601 in CAR-relapsed lymphoma.<\/p>\n<p align=\"justify\">\u201cThe awards funded reflect the extraordinary innovation taking place across Texas,&#8221; said CPRIT Chief Executive Officer Kristen Doyle, commenting on CPRIT\u2019s latest funding awards. &#8220;These investments support researchers, clinicians, entrepreneurs, and community leaders who are helping shape the future of cancer care and bringing new hope to Texans and Texas families.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About the Cancer Prevention and Research Institute of Texas (CPRIT)<\/strong><br \/>\n        <br \/>Created by the Texas Legislature and approved by Texas voters in 2007, the Cancer Prevention and Research Institute of Texas (CPRIT) is the state&#8217;s premier agency for advancing cancer research, prevention, and innovation. In 2019, Texans overwhelmingly reaffirmed their commitment to CPRIT by approving an additional $3 billion in funding, bringing the state&#8217;s total investment to $6 billion.<\/p>\n<p align=\"justify\">Since its inception, CPRIT has awarded more than $4 billion in grants to Texas research institutions and organizations through its academic research, prevention, and product development programs. CPRIT-funded investments have helped recruit 370 distinguished researchers to Texas, supported the establishment, expansion, or relocation of 90 companies, and delivered 13 million cancer prevention services across all 254 Texas counties.<\/p>\n<p align=\"justify\">\n        <strong>About MT-601<\/strong><br \/>\n        <br \/>The Company\u2019s lead product, MT-601 (neldaleucel), is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in lymphoma cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Company-sponsored Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are not candidates for anti-CD19 CAR-T cell therapies.<\/p>\n<p align=\"justify\">\n        <strong>About APOLLO <\/strong><br \/>\n        <br \/>The APOLLO trial (clinicaltrials.gov Identifier: NCT05798897) is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 (neldaleucel) in participants with relapsed or refractory lymphoma who have either failed anti-CD19 chimeric antigen receptor (CAR) T cell therapy or are not candidates for anti-CD19 CAR-T cell therapy. The primary objective of this exploratory Phase 1 clinical trial is to evaluate the optimum dose, safety, and preliminary efficacy of MT-601 in participants with various lymphoma subtypes. The APOLLO study is supported by competitive federal and state research grants, including from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Cancer Institute of the National Institutes of Health (Award Number R44CA291521).<\/p>\n<p align=\"justify\">\n        <strong>About MAR-T cells<\/strong><br \/>\n        <br \/>The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient&#8217;s\/donor\u2019s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.<\/p>\n<p align=\"justify\">\n        <strong>About Marker Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company\u2019s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker\u2019s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker\u2019s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research, including the National Cancer Institute of National Institutes of Health, U.S. Department of War, the FDA Orphan Drug program and the Cancer Prevention Research Institute of Texas (CPRIT).<\/p>\n<p align=\"justify\">To receive future press releases via email, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nL4AZCnwnwNZyxiptDJgWqp7ku-fLZXZBzOXT7octzpevu6uixl4lCTCNosoUdNLLHqs3DSXzK7hl1GlhHPN3VmHvGl3kjdbz-N3GeeTnn-ioQZfOyKD7yycKDBjtJWprkJZsvFF3xXnacuVsCXOh1ORtY0wqZ87_S4hLmmOM90=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.markertherapeutics.com\/email-alerts<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company\u2019s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are \u201cforward-looking statements.\u201d Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including neldaleucel (MT-601) for the treatment of patients with pancreatic cancer or lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company\u2019s most recent Form 10-K, 10-Q and other\u00a0SEC\u00a0filings which are available through EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-vkoTVloZOZXmnP7Nrzq2LyPDDc8tkj3jQepcl7rYAWfCUFQ1of0Fg0Znhfetez_jHQZDn91uOnLwddGHt5XAw==\" rel=\"nofollow\" target=\"_blank\">WWW.SEC.GOV<\/a>. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.<\/p>\n<p align=\"justify\">\n        <strong>Media and Investor Contact<\/strong>\n      <\/p>\n<p>Marker Therapeutics, Inc. <br \/>+1 (713) 400-6400 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KtVufSGX6Tji3aIyZGBeF9bQnbSyeoOjJ_hw8t26VChinSexJil88JPbjAon7QAI0EARd2dkb4gHPwwrdx225YTA3UOz2VlxZvWT8khsR_iGRfeBKGr3_JXJfNf269CC2fSzb0oUurNGBezltGHdUsJ3VVooLuMCpjwFHoKXhtQ=\" rel=\"nofollow\" target=\"_blank\">investor.relations@markertherapeutics.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGRjNWE2NTQtYTA0Ny00MWUzLWIyZjUtZDM2NDk2NDdhMjUxLTExOTkyNzEtMjAyNi0xMS0xOS1lbg==\/tiny\/Marker-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1022495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The &hellip; Continue reading &quot;Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T12:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study\",\"datePublished\":\"2026-11-19T12:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/\"},\"wordCount\":1519,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/\",\"name\":\"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\",\"datePublished\":\"2026-11-19T12:06:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/","og_locale":"en_US","og_type":"article","og_title":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk","og_description":"Highly competitive grant award provides significant non-dilutive funding to support Phase 2 development of MT-601 in CAR-relapsed lymphoma CPRIT award builds on encouraging Phase 1 clinical results, with additional patient data and updated response durability data expected later this year Independent scientific, clinical, and commercial review reinforces the potential of MT-601 in relapsed large B-cell lymphoma HOUSTON, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The &hellip; Continue reading \"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-19T12:06:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study","datePublished":"2026-11-19T12:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/"},"wordCount":1519,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/","name":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=","datePublished":"2026-11-19T12:06:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg4MTE0NiM3OTc1NzI1IzIxODc3MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1022495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1022495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1022495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1022495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1022495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}